行情

FATE

FATE

Fate
NASDAQ

实时行情|Nasdaq Last Sale

22.18
-1.13
-4.85%
盘后: 22.18 0 0.00% 16:56 03/27 EDT
开盘
22.86
昨收
23.31
最高
23.38
最低
21.86
成交量
85.62万
成交额
--
52周最高
32.39
52周最低
12.59
市值
16.84亿
市盈率(TTM)
-15.4468
分时
5日
1月
3月
1年
5年

分析师评级

16位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测FATE价格均价为37.94,最高价位57.00,最低价为28.00。

EPS

FATE 新闻

更多
  • 美股与美国经济,谁带崩了谁?
  • 证券市场红周刊 · 2小时前
  • 5G iPhone仍有望如期推出 供应商否认被告知延迟出货
  • TechWeb · 3小时前
  • 受疫情影响 泰国七家航空公司向政府提出紧急财政救援
  • 央视 · 3小时前
  • 国际劳工组织总干事:新冠肺炎疫情暴露当前全球经济脆弱性
  • 央视 · 4小时前

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

FATE 简况

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
展开

微牛提供Fate Therapeutics Inc(NASDAQ-FATE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的FATE股票新闻,以帮助您做出投资决策。